Fulcrum Therapeutics Inc (FULC): Not A Time To Panic Nor Freeze

Fulcrum Therapeutics Inc (FULC) concluded trading on Wednesday at a closing price of $6.36, with 0.39 million shares of worth about $2.48 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 60.61% during that period and on June 18, 2025 the price saw a loss of about -1.09%. Currently the company’s common shares owned by public are about 53.98M shares, out of which, 47.85M shares are available for trading.

Stock saw a price change of -6.88% in past 5 days and over the past one month there was a price change of -8.23%. Year-to-date (YTD), FULC shares are showing a performance of 35.32% which decreased to -14.63% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.32 but also hit the highest price of $10.13 during that period. The average intraday trading volume for Fulcrum Therapeutics Inc shares is 551.31K. The stock is currently trading -6.10% below its 20-day simple moving average (SMA20), while that difference is up 18.50% for SMA50 and it goes to 49.48% higher than SMA200.

Fulcrum Therapeutics Inc (NASDAQ: FULC) currently have 53.98M outstanding shares and institutions hold larger chunk of about 85.60% of that.

The stock has a current market capitalization of $343.31M and its 3Y-monthly beta is at 2.42. It has posted earnings per share of -$0.07 in the same period. It has Quick Ratio of 28.71 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for FULC, volatility over the week remained 2.82% while standing at 3.15% over the month.

Stock’s fiscal year EPS is expected to drop by -630.36% while it is estimated to decrease by -1.22% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on May 23, 2025 offering an Outperform rating for the stock and assigned a target price of $12 to it. Coverage by Cantor Fitzgerald stated Fulcrum Therapeutics Inc (FULC) stock as an Overweight in their note to investors on May 15, 2025, suggesting a price target of $10 for the stock. Stock get a Sector perform rating from RBC Capital Mkts on September 12, 2024.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.